azd5335
mAbexperimentalADC
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jun 5, 2023 (NCT05797168)
Timeline
Indications
Mechanism of action
- Folate receptor alphaBINDING AGENT
FOLR1 binding agent
Chemistry & pharmacology
- Payload
- unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07218809 | Phase 3 | Nov 28, 2025 | AstraZeneca, European Network for Gynaecological Oncological Trial, GOG Foundation, Inc. |
| NCT05797168 | Phase 1/Phase 2 (Phase 2) | Jun 5, 2023 | AstraZeneca, University of Texas at Houston |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 2 | 2 | 2 | 2023 |
| European Network for Gynaecological Oncological Trial | Academic/Hospital | 1 | 0 | 1 | 2025 |
| GOG Foundation, Inc. | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1